Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Inclusion Criteria: 1. HIV-1 infected adults (=/+18 years old). 2. Patient having a diagnosis of HIV infection, on stable HAART including 2 NRTI/NtRTIs plus one of the following: 1 PI/ritonavir or ATV/unboosted or 1 NNRTI. 3. Undetectable plasma HIV-1 RNA (VL \< 50 copies/mL) while on HAART. 4. Patient having at least one of the following conditions: * Antiretroviral-related gastrointestinal disturbances, or * Low patient's satisfaction associated with the current regimen posology (ritonavir use, ritonavir intolerance…), or * Any toxicity drug related. 5. Nadir CD4 cell count \> 350 cells/mm3. 6. Absence of resistance mutations in the RT or PR by (TrugeneTM) 7. Good treatment adherence. 8. Voluntary written informed consent. Exclusion Criteria: 1. Virologic failure to a previous antiretroviral regimen. 2. Any antiretroviral resistance mutation in a previous resistance test. 3. Dual/mixed or X4 viruses detected at any time point, including the pre-treatment ES-Trofile test of the PBMC test done before treatment switch. 4. Acute infections or uncontrolled chronic infection in the 2 months previous to the inclusion. 5. Pregnancy or fertile women willing to be pregnant.